par Clotet, Bonaventura;Bellos, Nicholas;Molina, Jean-Michel;Cooper, David;Goffard, Jean-Christophe ;Lazzarin, Adriano;Wöhrmann, Andrej;Katlama, Christine;Wilkin, Timothy;Haubrich, Richard;Cohen, Calvin;Farthing, Charles;Jayaweera, Dushyantha;Markowitz, Martin;Ruane, Peter;Spinosa-Guzman, Sabrina;Lefebvre, Eric;POWER 1 and 2 study groups,
Référence Lancet, 369, 9568, page (1169-1178)
Publication Publié, 2007-04
Référence Lancet, 369, 9568, page (1169-1178)
Publication Publié, 2007-04
Article révisé par les pairs
Résumé : | The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs). |